Antibody Drug Conjugates: A Pillar of Oncology Innovation

Explore ADC deal trends, pipeline growth, and why execution excellence is now a key differentiator.

Patient-reported unmet need in Acute Myeloid Leukaemia (AML) and Colorectal Cancer (CRC): Long-term support for patients and their caregivers is still lacking

Effects of KEAP1 silencing on NRF2 and NOTCH pathways in SCLC cell lines

The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study

International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

Uptake of Novel Therapies Into First-Line Treatment for Acute Myeloid Leukemia Patients: EU4 + UK Perspective

DLBCL Asia-Pacific Insights and Experiences

Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

Systemic therapy for oligoprogression in patients with metastatic NSCLC harboring activating EGFR mutations

PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors

Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape

In the Eye of the Storm: PD-(L)1 Inhibitors Weathering Turbulence

Combinations take centre stage in PD1/PDL1 inhibitor clinical trials

Trends in Clinical Development for PD-1/PD-L1 Inhibitors

Radiopharmaceuticals Take Center Stage in Global R&D

Translating Insights into Scalable Radioligand Trial Execution

FDA’s Draft Guidance on Dosage Optimization for Oncology Therapeutic Radiopharmaceuticals

Radiopharmaceuticals: A Transformative Force in Oncology Drug Development

Radiation Therapy Quality Assurance in Clinical Trials

IQVIA's Experience and Expertise in Radiopharmaceutical Clinical Trials

Breaking New Ground: Advancing Cancer Care with Novel Therapeutic Modalities